For the purpose of this study, we used a human model that mimics a sufficient mild systemic inflammatory response that allowed us to confirm the anti-inflammatory effect of OnabotA in chronic migraine as those subjects with untreated periodontitis and increased concentrations of CGRP and IL-6 responded better to this therapy than those without periodontitis. Here, IL6 is linked to periodontitis.